Logo

MTVA

MetaVia Inc.

MTVA

MetaVia Inc. • NASDAQ
$0.78 ▲ 3.71% (+0.03)
Market Cap $18.83 M
52w High $2.75
52w Low $0.56
Dividend Yield 0%
P/E -0.82
Volume 171.22K
Outstanding Shares 24.21M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.475M ▼ $-3.377M ▲ 0% $-0.14 ▲ $-3.47M ▲
Q2-2025 $0 $4.296M ▲ $-3.995M ▼ 0% $-0.26 ▲ $-3.99M ▼
Q1-2025 $0 $3.886M ▼ $-3.671M ▲ 0% $-0.36 ▲ $-3.882M ▲
Q4-2024 $0 $5.585M ▼ $-5.173M ▲ 0% $-0.6 ▼ $-5.58M ▲
Q3-2024 $0 $6.259M $-5.652M 0% $-0.55 $-6.254M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $14.277M ▼ $14.765M ▼ $8.434M ▼ $6.331M ▼
Q2-2025 $17.591M ▲ $18.459M ▲ $8.835M ▲ $9.624M ▲
Q1-2025 $11.19M ▼ $12.127M ▼ $7.747M ▼ $4.38M ▼
Q4-2024 $16.017M ▼ $16.26M ▼ $8.329M ▼ $7.931M ▼
Q3-2024 $21.669M $22.146M $9.193M $12.953M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-3.995M ▲ $-3.071M ▲ $-2K ▼ $9.472M ▲ $6.399M ▲ $-3.073M ▲
Q4-2024 $-5.173M ▲ $-5.428M ▲ $0 $-224K ▲ $-5.652M ▲ $-5.428M ▲
Q3-2024 $-5.652M ▲ $-5.589M ▲ $0 ▲ $-676K ▼ $-6.265M ▼ $-5.589M ▲
Q2-2024 $-10.053M ▼ $-7.251M ▼ $-3K ▲ $19.2M ▲ $11.946M ▲ $-7.254M ▼
Q1-2024 $-6.714M $-6.442M $-5K $0 $-6.447M $-6.447M

Five-Year Company Overview

Income Statement

Income Statement MetaVia is still a pure research and development story, with no product sales yet. Its expenses are fairly modest but consistently higher than its income, leading to ongoing losses each year. The loss levels appear relatively stable rather than sharply accelerating, which suggests disciplined cost control, but it also underscores that the company remains firmly in the investment phase rather than the revenue-generating phase. Earnings per share figures look extreme mainly because of the company’s very small equity base and past share structure changes, not because the absolute level of losses is huge.

Balance Sheet

Balance Sheet The balance sheet is simple and lean. Assets are mostly cash, with no reported debt, which reduces financial risk from lenders. Equity is positive but small, indicating a thin capital cushion. Overall, MetaVia looks like a typical early-stage biotech: a small pile of cash, little in the way of physical assets, and full reliance on that cash to fund its research programs. The limited size of the balance sheet means future capital raises are very likely as development progresses.

Cash Flow

Cash Flow Cash flow from operations is consistently negative, reflecting ongoing spending on clinical trials and overhead without any offsetting product revenue. Free cash flow tracks closely with operating cash flow, since capital spending on equipment and facilities is minimal. This indicates a “light” infrastructure model but also highlights that the business burns cash steadily and depends on periodic infusions of new capital to maintain its research pace.

Competitive Edge

Competitive Edge MetaVia operates in one of the most competitive and high-potential areas of biotech: treatments for obesity and metabolic liver disease. Its edge comes from differentiated drug designs, such as a dual-acting obesity drug aiming for deeper weight loss and an oral therapy for liver disease that could be more convenient than injections. Strategic use of AI partnerships to find new uses for its compounds adds to its positioning. At the same time, it competes against very large pharma players with established obesity and liver programs, so clinical results and partnerships will be crucial to sustain any advantage.

Innovation and R&D

Innovation and R&D The company’s value is concentrated in a small number of innovative drug candidates. The lead obesity drug uses a combined mechanism intended to both reduce appetite and increase energy use, targeting better and more durable weight loss. The lead liver drug targets inflammation, scarring, and blood sugar control in one pill, which could be attractive if trials confirm the benefits. MetaVia is also experimenting with AI-driven discovery to broaden the uses of its compounds. The main R&D risk is that these programs are still in early-to-mid clinical stages, with success far from guaranteed and a lot riding on a few core assets.

Summary

MetaVia is a classic clinical-stage biotech: no revenue, modest but persistent cash burn, and a small, debt-free balance sheet centered on cash. The company’s story is almost entirely about its science and trial outcomes rather than current financial performance. Its focus on obesity and metabolic liver disease puts it in a large and growing market, but one filled with powerful competitors. If its dual-acting obesity drug and oral liver therapy produce strong, safe, and differentiated results, MetaVia could strengthen its standing considerably; if not, its limited resources and narrow pipeline focus heighten the impact of setbacks. Financially, the path forward depends on successful trial milestones and continued access to capital to fund the next stages of development.

NEWS

November 7, 2025 · 8:31 AM UTC

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Read more

November 6, 2025 · 8:31 AM UTC

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 4, 2025 · 4:01 PM UTC

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Read more

October 27, 2025 · 8:31 AM UTC

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Read more

October 20, 2025 · 8:31 AM UTC

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Read more